Revium Rx (RVRC) Common Equity (2024 - 2025)

Revium Rx recorded quarterly Common Equity of $6.9 million in Q4 2025, down 65.08% quarter-over-quarter from $19.7 million in Q4 2024, and down 65.08% year-over-year from $19.7 million in Q4 2024.

Revium Rx's Common Equity history runs 2 years deep, the most recent figure standing at $6.9 million for Q4 2025.

  • In Q4 2025, Common Equity fell 65.08% year-over-year to $6.9 million; the TTM figure through Dec 2025 stood at $6.9 million (down 65.08% YoY), while the FY2025 annual figure was $6.9 million, down 65.08% from the prior year.
  • Common Equity came in at $6.9 million for Q4 2025 at Revium Rx, down from $19.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $19.7 million in Q4 2024 to a low of $6.9 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Veeva Systems 30.85 Bn 24.28 Bn 622.47 Mn 7.21 Bn
2 BrightSpring Health Services 12.29 Bn 11.41 Bn 482.22 Mn 1.98 Bn
3 Healthequity 7.80 Bn 7.48 Bn 256.31 Mn 2.05 Bn
4 Hinge Health 4.82 Bn 4.51 Bn 154.23 Mn 111.69 Mn
5 Doximity 4.21 Bn 3.46 Bn 125.97 Mn 950.84 Mn
6 Waystar Holding 4.18 Bn 4.03 Bn 268.04 Mn 3.94 Bn
7 10x Genomics 3.78 Bn 3.24 Bn 106.18 Mn 814.32 Mn
8 Privia Health 2.65 Bn 2.28 Bn 595.71 Mn 753.06 Mn
9 Omnicell 1.95 Bn 1.78 Bn 140.36 Mn 1.26 Bn
10 Revium Rx - - - 6.88 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 6.88 Mn
Dec 31, 2024 19.71 Mn